Subtype
Gastric Adenocarcinoma
CI-CAN-00005355STADExplore in graph →
137 active trials3 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005355STADExplore in graph →
Clinical trials
448 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05514769 | Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer | recruiting | N/A | 60 | Nanchong Central HospitalOTHER_GOV | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT06943781 | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection | recruiting | — | 15,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07405931 | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients | recruiting | N/A | 414 | Ulsan University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06370143 | A Study Collecting Health Information to Understand and Prevent Gastric Cancer | recruiting | — | 3,200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04290806 | Registry Platform Gastric/Esophageal Cancer (SAPHIR)(SAPHIR) | recruiting | — | 1,900 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07059299 | A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma(NeoTISLEGA) | recruiting | Phase 1 | 18 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07029269 | Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer | recruiting | Phase 3 | 454 | Zuoyi JiaoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07253948 | Distribution Characteristics of Helicobacter Pylori | recruiting | — | 231 | Jilin UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06675136 | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04665687 | Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients | recruiting | — | 1,730 | Samsung Medical CenterOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07034742 | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | recruiting | Early Phase 1 | 136 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04850729 | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | recruiting | — | 169 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06962293 | Magnetic Guided Counetrtraction During Endoscopic Submucosal Dissection | recruiting | N/A | 20 | Chinese University of Hong KongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT05804331 | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study(ANZ UGI) | recruiting | — | 500 | Western Sydney Local Health DistrictOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06289374 | Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery(LABS) | recruiting | — | 100 | Imperial College LondonOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06798376 | Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer | recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06748352 | Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer | recruiting | N/A | 50 | Shandong UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06466902 | Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)(PhotoNodes) | recruiting | — | 326 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06389448 | Comparison of pCLE and EB in Gastric Lesion Diagnosis | recruiting | N/A | 366 | Huazhong University of Science and TechnologyOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04047953 | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | recruiting | N/A | 95 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05723718 | MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment(MOONRISE) | recruiting | — | 125 | Medical University of LublinOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05323929 | The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma | recruiting | N/A | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05291728 | Screening for Early Gastric Cancer in Shaanxi Province | recruiting | — | 12,500,000 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2026source: clinicaltrials